Cargando…

Nanosystems for gene therapy targeting brain damage caused by viral infections

Several human pathogens can cause long-lasting neurological damage. Despite the increasing clinical knowledge about these conditions, most still lack efficient therapeutic interventions. Gene therapy (GT) approaches comprise strategies to modify or adjust the expression or function of a gene, thus p...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Talita Nascimento, de Lima, Emanuelle V., Barradas, Thaís Nogueira, Testa, Carla G., Picciani, Paulo H.S., Figueiredo, Claudia P., do Carmo, Flavia A., Clarke, Julia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816812/
https://www.ncbi.nlm.nih.gov/pubmed/36619201
http://dx.doi.org/10.1016/j.mtbio.2022.100525
_version_ 1784864623936143360
author da Silva, Talita Nascimento
de Lima, Emanuelle V.
Barradas, Thaís Nogueira
Testa, Carla G.
Picciani, Paulo H.S.
Figueiredo, Claudia P.
do Carmo, Flavia A.
Clarke, Julia R.
author_facet da Silva, Talita Nascimento
de Lima, Emanuelle V.
Barradas, Thaís Nogueira
Testa, Carla G.
Picciani, Paulo H.S.
Figueiredo, Claudia P.
do Carmo, Flavia A.
Clarke, Julia R.
author_sort da Silva, Talita Nascimento
collection PubMed
description Several human pathogens can cause long-lasting neurological damage. Despite the increasing clinical knowledge about these conditions, most still lack efficient therapeutic interventions. Gene therapy (GT) approaches comprise strategies to modify or adjust the expression or function of a gene, thus providing therapy for human diseases. Since recombinant nucleic acids used in GT have physicochemical limitations and can fail to reach the desired tissue, viral and non-viral vectors are applied to mediate gene delivery. Although viral vectors are associated to high levels of transfection, non-viral vectors are safer and have been further explored. Different types of nanosystems consisting of lipids, polymeric and inorganic materials are applied as non-viral vectors. In this review, we discuss potential targets for GT intervention in order to prevent neurological damage associated to infectious diseases as well as the role of nanosized non-viral vectors as agents to help the selective delivery of these gene-modifying molecules. Application of non-viral vectors for delivery of GT effectors comprise a promising alternative to treat brain inflammation induced by viral infections.
format Online
Article
Text
id pubmed-9816812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98168122023-01-07 Nanosystems for gene therapy targeting brain damage caused by viral infections da Silva, Talita Nascimento de Lima, Emanuelle V. Barradas, Thaís Nogueira Testa, Carla G. Picciani, Paulo H.S. Figueiredo, Claudia P. do Carmo, Flavia A. Clarke, Julia R. Mater Today Bio Review Article Several human pathogens can cause long-lasting neurological damage. Despite the increasing clinical knowledge about these conditions, most still lack efficient therapeutic interventions. Gene therapy (GT) approaches comprise strategies to modify or adjust the expression or function of a gene, thus providing therapy for human diseases. Since recombinant nucleic acids used in GT have physicochemical limitations and can fail to reach the desired tissue, viral and non-viral vectors are applied to mediate gene delivery. Although viral vectors are associated to high levels of transfection, non-viral vectors are safer and have been further explored. Different types of nanosystems consisting of lipids, polymeric and inorganic materials are applied as non-viral vectors. In this review, we discuss potential targets for GT intervention in order to prevent neurological damage associated to infectious diseases as well as the role of nanosized non-viral vectors as agents to help the selective delivery of these gene-modifying molecules. Application of non-viral vectors for delivery of GT effectors comprise a promising alternative to treat brain inflammation induced by viral infections. Elsevier 2022-12-17 /pmc/articles/PMC9816812/ /pubmed/36619201 http://dx.doi.org/10.1016/j.mtbio.2022.100525 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
da Silva, Talita Nascimento
de Lima, Emanuelle V.
Barradas, Thaís Nogueira
Testa, Carla G.
Picciani, Paulo H.S.
Figueiredo, Claudia P.
do Carmo, Flavia A.
Clarke, Julia R.
Nanosystems for gene therapy targeting brain damage caused by viral infections
title Nanosystems for gene therapy targeting brain damage caused by viral infections
title_full Nanosystems for gene therapy targeting brain damage caused by viral infections
title_fullStr Nanosystems for gene therapy targeting brain damage caused by viral infections
title_full_unstemmed Nanosystems for gene therapy targeting brain damage caused by viral infections
title_short Nanosystems for gene therapy targeting brain damage caused by viral infections
title_sort nanosystems for gene therapy targeting brain damage caused by viral infections
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816812/
https://www.ncbi.nlm.nih.gov/pubmed/36619201
http://dx.doi.org/10.1016/j.mtbio.2022.100525
work_keys_str_mv AT dasilvatalitanascimento nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT delimaemanuellev nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT barradasthaisnogueira nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT testacarlag nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT piccianipaulohs nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT figueiredoclaudiap nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT docarmoflaviaa nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections
AT clarkejuliar nanosystemsforgenetherapytargetingbraindamagecausedbyviralinfections